Literature DB >> 25961697

MicroRNA and ALK-positive anaplastic large cell lymphoma.

Coralie Hoareau-Aveilla, Olaf Merkel, Fabienne Meggetto1.   

Abstract

In this review we describe the current literature covering the role of microRNA in anaplastic large cell lymphoma (ALCL). MicroRNA is one of the best characterized subgroups of non-coding RNAs and it is now becoming clear that its importance in oncogenesis has been greatly underestimated. In ALCL the deregulation of a diverse range of microRNA has been demonstrated however much less is known about the physiological consequences of this deregulation. Here we focus on the subgroup of ALCL bearing the anaplastic lymphoma kinase (ALK) translocation (ALK+). The pathways linking oncogenic ALK signaling and the regulation of microRNA are now becoming established with the transcription factor STAT3 appearing to play an important role in the epigenetic regulation. This review will discuss our current understanding of the role of microRNAs in ALK-mediated oncogenesis and will explain why we believe these new findings suggest that the use of methyltransferase inhibitors together with microRNA-specific drugs could be a useful addition to our current armamentarium in the fight against ALK(+) ALCL.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25961697     DOI: 10.2741/S435

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  7 in total

1.  High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells.

Authors:  Domenico Sorrentino; Julie Frentzel; Géraldine Mitou; Rafael B Blasco; Avédis Torossian; Coralie Hoareau-Aveilla; Chiara Pighi; Manon Farcé; Fabienne Meggetto; Stéphane Manenti; Estelle Espinos; Roberto Chiarle; Sylvie Giuriato
Journal:  Cancers (Basel)       Date:  2020-10-13       Impact factor: 6.639

2.  Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.

Authors:  Waseem Lone; Alyssa Bouska; Sunandini Sharma; Catalina Amador; Mallick Saumyaranjan; Tyler A Herek; Tayla B Heavican; Jiayu Yu; Soon Thye Lim; Choon Kiat Ong; Graham W Slack; Kerry J Savage; Andreas Rosenwald; German Ott; James R Cook; Andrew L Feldman; Lisa M Rimsza; Timothy W McKeithan; Timothy C Greiner; Dennis D Weisenburger; Federica Melle; Giovanna Motta; Stefano Pileri; Julie M Vose; Wing C Chan; Javeed Iqbal
Journal:  Clin Cancer Res       Date:  2021-08-23       Impact factor: 13.801

Review 3.  Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

Authors:  Coralie Hoareau-Aveilla; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

4.  miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.

Authors:  Coralie Hoareau-Aveilla; Cathy Quelen; Annabelle Congras; Nina Caillet; Delphine Labourdette; Christine Dozier; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

Review 5.  NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.

Authors:  Elissa Andraos; Joséphine Dignac; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

6.  IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.

Authors:  Cecilia Bandini; Aldi Pupuleku; Elisa Spaccarotella; Elisa Pellegrino; Rui Wang; Nicoletta Vitale; Carlotta Duval; Daniela Cantarella; Andrea Rinaldi; Paolo Provero; Ferdinando Di Cunto; Enzo Medico; Francesco Bertoni; Giorgio Inghirami; Roberto Piva
Journal:  Cancers (Basel)       Date:  2018-01-18       Impact factor: 6.639

7.  Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells.

Authors:  Annabelle Congras; Nina Caillet; Nouritza Torossian; Cathy Quelen; Camille Daugrois; Pierre Brousset; Laurence Lamant; Fabienne Meggetto; Coralie Hoareau-Aveilla
Journal:  Oncotarget       Date:  2018-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.